No abstract available
Publication types
-
Editorial
-
Research Support, N.I.H., Intramural
-
Comment
MeSH terms
-
Genomics
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
-
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell* / therapy
-
Mutation
-
Precision Medicine
Grants and funding
Funding: Support received for work outside the submitted work: Adrian Wiestner received research support from Pharmacyclics LLC, an AbbVie company; Acerta Pharma, a member of the Astra-Zeneca group; Merck; Nurix; and Genmab. The author is supported by the intramural research program of NHLBI, NIH.